These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 2955539)
1. Hemorrhagic thrombocytopathy with platelet thromboxane A2 receptor abnormality: defective signal transduction with normal binding activity. Ushikubi F; Okuma M; Kanaji K; Sugiyama T; Ogorochi T; Narumiya S; Uchino H Thromb Haemost; 1987 Apr; 57(2):158-64. PubMed ID: 2955539 [TBL] [Abstract][Full Text] [Related]
2. Analysis of the defective signal transduction mechanism through the platelet thromboxane A2 receptor in a patient with polycythemia vera. Ushikubi F; Ishibashi T; Narumiya S; Okuma M Thromb Haemost; 1992 Jan; 67(1):144-6. PubMed ID: 1535462 [TBL] [Abstract][Full Text] [Related]
3. Defective signal transduction through the thromboxane A2 receptor in a patient with a mild bleeding disorder: deficiency of the inositol 1,4,5-triphosphate formation despite normal G-protein activation. Mitsui T; Yokoyama S; Shimizu Y; Katsuura M; Akiba K; Hayasaka K Thromb Haemost; 1997 May; 77(5):991-5. PubMed ID: 9184416 [TBL] [Abstract][Full Text] [Related]
4. Binding of an 125I-labeled thromboxane A2/prostaglandin H2 receptor antagonist to washed canine platelets. Mais DE; Kochel PJ; Saussy DL; Halushka PV Mol Pharmacol; 1985 Aug; 28(2):163-9. PubMed ID: 2991736 [TBL] [Abstract][Full Text] [Related]
5. Defective signal transduction induced by thromboxane A2 in a patient with a mild bleeding disorder: impaired phospholipase C activation despite normal phospholipase A2 activation. Fuse I; Mito M; Hattori A; Higuchi W; Shibata A; Ushikubi F; Okuma M; Yahata K Blood; 1993 Feb; 81(4):994-1000. PubMed ID: 8428006 [TBL] [Abstract][Full Text] [Related]
6. Pathogenetic analysis of five cases with a platelet disorder characterized by the absence of thromboxane A2 (TXA2)-induced platelet aggregation in spite of normal TXA2 binding activity. Fuse I; Hattori A; Mito M; Higuchi W; Yahata K; Shibata A; Aizawa Y Thromb Haemost; 1996 Dec; 76(6):1080-5. PubMed ID: 8972034 [TBL] [Abstract][Full Text] [Related]
7. Binding of a thromboxane A2/prostaglandin H2 receptor antagonist to washed human platelets. Mais DE; Burch RM; Saussy DL; Kochel PJ; Halushka PV J Pharmacol Exp Ther; 1985 Dec; 235(3):729-34. PubMed ID: 3001275 [TBL] [Abstract][Full Text] [Related]
8. Hypersensitivity to thromboxane A2 in cholesterol-rich human platelets. Tomizuka T; Yamamoto K; Hirai A; Tamura Y; Yoshida S Thromb Haemost; 1990 Dec; 64(4):594-9. PubMed ID: 2150728 [TBL] [Abstract][Full Text] [Related]
10. [PI metabolism and Ca mobilization in patients with platelet dysfunction]. Fuse I; Hattori A; Higuchi W; Shibata A Nihon Rinsho; 1992 Feb; 50(2):237-43. PubMed ID: 1535386 [TBL] [Abstract][Full Text] [Related]
11. Molecular characterization of a dominantly inherited bleeding disorder with impaired platelet responses to thromboxane A2. Okuma M; Hirata T; Ushikubi F; Kakizuka A; Narumiya S Pol J Pharmacol; 1996; 48(1):77-82. PubMed ID: 9112632 [TBL] [Abstract][Full Text] [Related]
12. Thromboxane-insensitive dog platelets have impaired activation of phospholipase C due to receptor-linked G protein dysfunction. Johnson GJ; Leis LA; Dunlop PC J Clin Invest; 1993 Nov; 92(5):2469-79. PubMed ID: 8227362 [TBL] [Abstract][Full Text] [Related]
13. Distinct platelet thromboxane A2/prostaglandin H2 receptor subtypes. A radioligand binding study of human platelets. Dorn GW J Clin Invest; 1989 Dec; 84(6):1883-91. PubMed ID: 2531760 [TBL] [Abstract][Full Text] [Related]
14. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors. Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481 [TBL] [Abstract][Full Text] [Related]